136 Long-term tiotropium bromide therapy was retrospectively analyzed in adults with cystic fibrosis

Abstract

Listen

Translate article

Objectives The chronic and life-limiting pulmonary disease caused by cystic fibrosis is often treated with bronchodilators. We investigated, for the first time, the effect of 24 months long-term tiotropium bromide therapy in people with cystic fibrosis on pulmonary lung function and risk of exacerbation. Methods In this retrospective cohort study, we compare 24 months of tiotropium bromide therapy with a non-tiotropium bromide treated control group. Data was obtained from local patient registry (MUKO.doc). Forty-nine patients with 18 mg once-daily inhaled tiotropium bromide therapy were selected. Forty-nine non-tiotropium bromide treated control patients were identified and matched by gender, age and forced expiratory volume in 1 second at the beginning of 24 month observation period (FEV1 0M ). The primary end point was the mean annual change of FEV1. The secondary end point included measures of exacerbation. Results The study included 98 patients, divided into tiotropium bromide treated (n = 49) and non-tiotropium bromide treated control patients (n = 49). Patients treated with tiotropium bromide showed an improvement of 0.6% of mean annual change of FEV1 (control: −1.0±5.0%; treated: +0.6±4.2%). Furthermore, tiotropium bromide therapy was associated with a slightly lower exacerbation risk. Mean annual change of number of exacerbations was improved in tiotropium bromide treated patients (control: +0.2±1.8; treated: −0.1±1.9). Tiotropium bromide was well tolerated in all patients. Conclusion In patients with cystic fibrosis, long-term therapy with tiotropium bromide was associated with a positive tendency in lung function and exacerbation risk.